Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18755058 | PCNA INHIBITORS | June 2024 | July 2025 | Allow | 12 | 1 | 0 | No | No |
| 18606778 | 3-(3-FLUOROPHENYL)-5-(4-METHOXYBENZYLTHIO)-4-PHENYL-4H-1,2,4-TRIAZOLE AS AN ANTIMICROBIAL COMPOUND | March 2024 | December 2024 | Allow | 9 | 1 | 1 | No | No |
| 18423156 | CARDIAC SARCOMERE INHIBITORS | January 2024 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18420478 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | January 2024 | February 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18526028 | ELECTROPHILIC NITROALKENE BENZOIC ACID DERIVATES AS THERAPEUTIC DRUGS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE CONDITIONS | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18522995 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | November 2023 | April 2025 | Allow | 16 | 2 | 0 | No | No |
| 18382812 | 3-(3-FLUOROPHENYL)-5-(4-METHOXYBENZYLTHIO)-4-PHENYL-4H-1,2,4-TRIAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | August 2024 | Abandon | 10 | 1 | 1 | No | No |
| 18381291 | ETHYL 6-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)HEXANOATE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 3 | 0 | 1 | No | No |
| 18381069 | ETHYL {[4-BENZOYL-5-(3-FLUOROPHENYL)-4H-1,2,4-TRIAZOL-3-YL]THIO}ACETATE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 0 | 1 | No | No |
| 18370519 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | September 2023 | September 2024 | Allow | 12 | 2 | 1 | No | No |
| 18108045 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | February 2023 | March 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18103371 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18103319 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18102983 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18103180 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18154520 | BENZOATE DERIVATIVES | January 2023 | April 2024 | Allow | 15 | 1 | 1 | No | No |
| 18078630 | DISELENIDE-BASED ORGANIC PROTECTIVE FILMS | December 2022 | October 2023 | Allow | 10 | 2 | 1 | No | No |
| 18062959 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, IMAGE PICKUP ELEMENT, AND IMAGE PICKUP APPARATUS | December 2022 | May 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17986207 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | November 2022 | September 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17982664 | FORMS AND COMPOSITIONS OF INHIBITORS OF JAK2 | November 2022 | July 2024 | Allow | 21 | 2 | 1 | No | No |
| 17978848 | SOLID FORMS OF(Z)-4-(5-((3-BENZYL-4-OXO-2-THIOXOTHIAZOLIDIN-5-YLIDENE)METHYL)FURAN-2-YL)BENZOIC ACID | November 2022 | October 2024 | Allow | 24 | 2 | 0 | No | No |
| 18045390 | STAT DEGRADERS AND USES THEREOF | October 2022 | January 2023 | Allow | 3 | 0 | 0 | No | No |
| 17939512 | PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | September 2022 | May 2023 | Abandon | 8 | 0 | 1 | No | No |
| 17889047 | ESTERS OF A RETINOID AND A TOCOPHEROL OR TERT-BUTYLHYDROQUINONE AND PREPARATIONS THEREOF | August 2022 | February 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17884292 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | August 2022 | June 2025 | Allow | 35 | 1 | 1 | No | No |
| 17875982 | IONIZABLE LIPIDOIDS AND THEIR USES | July 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17862071 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | July 2022 | June 2024 | Allow | 24 | 1 | 0 | No | No |
| 17849949 | Cytotoxic Actin-Targeting Compounds | June 2022 | November 2024 | Allow | 28 | 2 | 0 | No | No |
| 17807389 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | June 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17830158 | ANTI-VIRAL DRUG | June 2022 | November 2024 | Allow | 30 | 1 | 1 | No | No |
| 17780047 | CANNABIGEROL DERIVATIVES AND USE THEREOF AS CANNABINOID RECEPTOR MODULATORS | May 2022 | April 2024 | Allow | 23 | 2 | 0 | No | No |
| 17752649 | BICYCLIC COMPOUNDS | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17662246 | INDOLE AHR INHIBITORS AND USES THEREOF | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17738166 | PROTEIN COMPLEX COMPRISING NON-PEPTIDYL POLYMER-COUPLED FATTY ACID DERIVATIVE COMPOUND AS LINKER AND PREPARATION METHOD THEREFOR | May 2022 | March 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17736669 | STAT DEGRADERS AND USES THEREOF | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17732724 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | April 2022 | September 2023 | Allow | 17 | 1 | 0 | No | No |
| 17661182 | HETERO-BICYCLIC INHIBITORS OF KRAS | April 2022 | June 2023 | Allow | 14 | 2 | 1 | No | Yes |
| 17730948 | PCNA INHIBITORS | April 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17729652 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION | April 2022 | April 2024 | Allow | 24 | 0 | 1 | No | No |
| 17704892 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | March 2022 | April 2025 | Allow | 36 | 3 | 0 | No | No |
| 17654547 | Bromodomain Inhibitors | March 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17687188 | CHEMICAL COMPOUNDS | March 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17685778 | CARDIAC SARCOMERE INHIBITORS | March 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17668519 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF | February 2022 | February 2025 | Allow | 36 | 1 | 0 | No | No |
| 17587304 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | January 2022 | May 2025 | Allow | 40 | 2 | 1 | No | No |
| 17575080 | COMPOSITIONS AND METHODS RELATING TO NOVEL SULFONO-gamma-AA PEPTIDES | January 2022 | August 2024 | Allow | 31 | 2 | 1 | No | No |
| 17556188 | TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR | December 2021 | May 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17595819 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | November 2021 | April 2025 | Abandon | 40 | 0 | 0 | No | No |
| 17595537 | AZEPINES AS HBV CAPSID ASSEMBLY MODULATORS | November 2021 | April 2025 | Abandon | 41 | 0 | 0 | No | No |
| 17452786 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | October 2021 | May 2024 | Allow | 30 | 1 | 0 | No | No |
| 17605750 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17506614 | DUAL-RESPONSIVE NANOPARTICLES FOR ENHANCED ANTIBACTERIAL EFFICACY | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17499433 | RAPAMYCIN DERIVATIVES | October 2021 | March 2024 | Allow | 29 | 1 | 0 | No | No |
| 17442206 | NOVEL DEPSIDE DIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | September 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17480424 | ENZYME INHIBITORS | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17479438 | ASYMMETRIC METAL COMPLEX AS AN ACTIVE MATERIAL OF A FLOW BATTERY | September 2021 | September 2024 | Allow | 36 | 2 | 1 | No | No |
| 17475733 | HETEROCYCLIC COMPOUND | September 2021 | April 2025 | Allow | 43 | 3 | 0 | No | No |
| 17474482 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | September 2021 | January 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17472371 | HUMAN TLR8-SELECTIVE AGONISTS | September 2021 | August 2024 | Allow | 35 | 2 | 0 | No | No |
| 17469535 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | September 2021 | January 2024 | Allow | 28 | 1 | 0 | No | No |
| 17458021 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | August 2021 | January 2024 | Allow | 29 | 1 | 1 | No | No |
| 17408792 | TOPICAL FORMULATIONS AND TREATMENTS | August 2021 | January 2025 | Allow | 41 | 3 | 1 | No | No |
| 17394630 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | August 2021 | April 2024 | Allow | 33 | 2 | 1 | No | No |
| 17382901 | PKC INHIBITOR SOLID STATE FORMS | July 2021 | June 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17378696 | 2-AMINOSELENOPHEN COMPOUNDS WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME | July 2021 | September 2023 | Abandon | 26 | 2 | 1 | No | No |
| 17376522 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | July 2021 | March 2024 | Allow | 32 | 3 | 0 | No | No |
| 17363841 | PRODUCTION OF NITROGEN-CONTAINING CHELATORS | June 2021 | December 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17346726 | Treatment of inflammation initiated by the spinal cord injury, the traumatic brain injury, stroke, in inhibition of cerebral and spinal cord edema and of inflammation in neurodegenerative, immune mediated and infectious diseases of the central nervous system. | June 2021 | February 2024 | Abandon | 32 | 1 | 2 | Yes | No |
| 17298540 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | May 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17244172 | SYSTEMS AND METHODS FOR PRODUCING NITRILES | April 2021 | December 2024 | Allow | 43 | 2 | 1 | No | No |
| 17239064 | SYSTEMS AND METHODS FOR PRODUCING NITRILES | April 2021 | January 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17301941 | AGGREGATION-INDUCED EMISSION LUMINOGENS USEFUL FOR CANCER CELL DISCRIMINATION AND MONITORING | April 2021 | January 2024 | Allow | 33 | 1 | 1 | No | No |
| 17226004 | CFTR REGULATORS AND METHODS OF USE THEREOF | April 2021 | May 2025 | Allow | 49 | 5 | 0 | No | No |
| 17208964 | ANTIVIRAL COMPOUNDS | March 2021 | January 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17208919 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | March 2021 | February 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17191806 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | March 2021 | October 2023 | Allow | 32 | 2 | 0 | No | No |
| 17249489 | Oral Care Composition Containing Cetylpyridinium Tetrachlorozincate | March 2021 | November 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17191552 | BIOACTIVE POLYMERS WITH ANTI=FOULING PROPERTIES FOR MEDICAL AND DENTAL USES | March 2021 | July 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17188625 | AMORPHOUS FORMS OF SELINEXOR AND PROCESS FOR THEIR PREPARATION | March 2021 | July 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17176847 | FLUOROGENIC CYANINE COMPOUNDS FOR DETECTING NUCLEIC ACIDS | February 2021 | July 2024 | Allow | 41 | 2 | 1 | No | No |
| 17173884 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | February 2021 | February 2023 | Allow | 24 | 2 | 0 | No | No |
| 17265993 | FUNGICIDAL MIXTURES FOR SOYBEAN DISEASES | February 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17159485 | GLP-1R MODULATING COMPOUNDS | January 2021 | August 2024 | Allow | 43 | 4 | 1 | No | No |
| 17157733 | ANTIVIRAL COMPOUNDS | January 2021 | May 2023 | Allow | 27 | 1 | 1 | No | No |
| 17145453 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | January 2021 | August 2023 | Allow | 31 | 1 | 1 | No | No |
| 17130022 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | December 2020 | November 2023 | Allow | 35 | 2 | 1 | No | No |
| 17255371 | INTERMEDIATES IN THE SYNTHESIS OF C3-SUBSTITUTED CEPHALOSPORINS | December 2020 | August 2023 | Allow | 32 | 2 | 1 | No | No |
| 17120217 | Advanced Formulations and Therapies for Treating Hard-to-Heal Wounds | December 2020 | April 2025 | Abandon | 53 | 1 | 1 | No | No |
| 16973587 | CHEMICAL COMPOUNDS | December 2020 | March 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17111339 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | December 2020 | March 2023 | Allow | 28 | 0 | 1 | No | No |
| 17058035 | METHOD FOR PRODUCING SUBSTITUTED N-ARYL PYRAZOLES | November 2020 | February 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17056267 | IMIDAZO-PYRAZOLE CARBOXAMIDE DERIVATIVES AS ANTICANCER AGENTS AND THE SYNTHESIS THEREOF | November 2020 | March 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17096721 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | November 2020 | January 2023 | Allow | 27 | 1 | 0 | No | No |
| 17054322 | AGGRESSIVE LIPID LOWERING THERAPY IN CORONARY ARTERY DISEASE | November 2020 | August 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17091247 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | November 2020 | June 2024 | Abandon | 43 | 3 | 1 | No | No |
| 17083895 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING KSP INHIBITOR AND MITOSIS INHIBITOR | October 2020 | October 2024 | Allow | 47 | 2 | 1 | No | No |
| 17080523 | ELECTROPHILIC NITROALKENE BENZOIC ACID DERIVATES AS THERAPEUTIC DRUGS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE CONDITIONS | October 2020 | December 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17073603 | METHODS FOR ENHANCING CELLULAR CLEARANCE OF PATHOLOGICAL MOLECULES VIA ACTIVATION OF THE CELLULAR PROTEIN YKT6 | October 2020 | October 2024 | Allow | 48 | 2 | 2 | No | No |
| 17071056 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | October 2020 | August 2023 | Allow | 34 | 2 | 1 | No | No |
| 17070620 | USE OF FAVIPIRAVIR IN TREATMENT OF CORONAVIRUS INFECTION | October 2020 | June 2023 | Abandon | 32 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, PO-CHIH.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHEN, PO-CHIH works in Art Unit 1621 and has examined 236 patent applications in our dataset. With an allowance rate of 80.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 32 months.
Examiner CHEN, PO-CHIH's allowance rate of 80.1% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHEN, PO-CHIH receive 1.93 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, PO-CHIH is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +10.4% benefit to allowance rate for applications examined by CHEN, PO-CHIH. This interview benefit is in the 47% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 52.8% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 42.1% are granted (fully or in part). This grant rate is in the 43% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 13.8% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.